BE2021C557I2 - - Google Patents
Info
- Publication number
- BE2021C557I2 BE2021C557I2 BE2021C557C BE2021C557C BE2021C557I2 BE 2021C557 I2 BE2021C557 I2 BE 2021C557I2 BE 2021C557 C BE2021C557 C BE 2021C557C BE 2021C557 C BE2021C557 C BE 2021C557C BE 2021C557 I2 BE2021C557 I2 BE 2021C557I2
- Authority
- BE
- Belgium
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2/00—Peptides of undefined number of amino acids; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Obesity (AREA)
- Reproductive Health (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Gynecology & Obstetrics (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US69777905P | 2005-07-08 | 2005-07-08 | |
| US74885005P | 2005-12-09 | 2005-12-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BE2021C557I2 true BE2021C557I2 (enExample) | 2026-01-14 |
Family
ID=37637790
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE2021C557C BE2021C557I2 (enExample) | 2005-07-08 | 2021-12-07 |
Country Status (21)
| Country | Link |
|---|---|
| US (8) | US8039435B2 (enExample) |
| EP (6) | EP3354273B1 (enExample) |
| JP (4) | JP4734411B2 (enExample) |
| KR (2) | KR101232201B1 (enExample) |
| CN (5) | CN101257916B (enExample) |
| AU (2) | AU2006269261B2 (enExample) |
| BE (1) | BE2021C557I2 (enExample) |
| CA (4) | CA2793119C (enExample) |
| DK (4) | DK3354273T3 (enExample) |
| ES (4) | ES2386862T3 (enExample) |
| FR (1) | FR21C1060I2 (enExample) |
| HU (4) | HUE037147T2 (enExample) |
| IL (3) | IL188545A (enExample) |
| NL (1) | NL301150I2 (enExample) |
| NZ (2) | NZ565217A (enExample) |
| PL (4) | PL2236151T3 (enExample) |
| PT (4) | PT2548568T (enExample) |
| RU (2) | RU2439079C2 (enExample) |
| SG (1) | SG163585A1 (enExample) |
| SI (1) | SI3354273T1 (enExample) |
| WO (1) | WO2007008704A2 (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2439079C2 (ru) * | 2005-07-08 | 2012-01-10 | Сосьете Де Консей Де Решерш Э Д'Аппликасьон Сьентифик С.А.С. | Лиганды рецепторов меланокортинов |
| DE102007020152A1 (de) * | 2007-04-26 | 2008-10-30 | Charité - Universitätsmedizin Berlin | Mittel zur antiinfektiven Behandlung eines Patienten |
| EP2148692B1 (en) | 2007-05-25 | 2017-01-25 | Ipsen Pharma S.A.S. | Melanocortin receptor ligands modified with hydantoin |
| EP2167112A4 (en) * | 2007-06-15 | 2012-01-25 | Ipsen Pharma Sas | CYCLIC PEPTIDE MELANOCORTIN RECEPTOR LIGANDS |
| CA2952095C (en) | 2007-11-05 | 2020-02-18 | Ipsen Pharma S.A.S. | Use of melanocortins to treat insulin sensitivity |
| MX356295B (es) | 2008-05-27 | 2018-05-22 | Genzyme Corp | Análogos de péptido de la hormona de estimulación de alfa-melanocito. |
| JP5628796B2 (ja) | 2008-06-09 | 2014-11-19 | パラティン テクノロジーズ, インコーポレイテッドPalatin Technologies, Inc. | 性的不能の治療用のメラノコルチンレセプタ特異的ペプチド |
| WO2010144344A2 (en) * | 2009-06-08 | 2010-12-16 | Palatin Technologies, Inc. | Melanocortin receptor-specific peptides |
| UY32690A (es) | 2009-06-08 | 2011-01-31 | Astrazeneca Ab | Péptidos específicos para receptores de melanocortina |
| WO2010144341A2 (en) | 2009-06-08 | 2010-12-16 | Palatin Technologies, Inc. | Lactam-bridged melanocortin receptor-specific peptides |
| CN102548399A (zh) * | 2009-08-05 | 2012-07-04 | 益普生制药股份有限公司 | 黑皮质素治疗血脂异常的用途 |
| US8541545B2 (en) * | 2009-08-31 | 2013-09-24 | Tensive Controls Inc. | Stabilized melanocortin ligands |
| US9314509B2 (en) | 2009-11-16 | 2016-04-19 | Ipsen Pharma S.A.S. | Pharmaceutical compositions of melanocortin receptor ligands |
| WO2011060355A1 (en) * | 2009-11-16 | 2011-05-19 | Ipsen Pharma S.A.S | Process for the synthesis of ac-arg-cyclo(cys-d-ala-his-d-phe-arg-trp-cys)-nh2 |
| EA201290295A1 (ru) | 2009-11-23 | 2013-01-30 | Палатин Текнолоджиз, Инк. | Специфичные к рецептору меланокортина-1 линейные пептиды |
| AU2010321738B2 (en) | 2009-11-23 | 2016-07-14 | Palatin Technologies, Inc. | Melanocortin-1 receptor-specific cyclic peptides |
| CA2833676C (en) * | 2011-06-14 | 2019-04-23 | Ipsen Pharma S.A.S. | A sustained-release composition containing peptides as active ingredient |
| HRP20211950T1 (hr) | 2011-12-29 | 2022-03-18 | Rhythm Pharmaceuticals, Inc. | Postupak liječenja poremećaja u vezi sa melanokortin-4 receptorom u heterozigotnim nosiocima |
| EP2705835A1 (en) | 2012-06-08 | 2014-03-12 | Ipsen Pharma S.A.S. | Aqueous gelling compositions of soluble active pharmaceutical peptides providing modified release |
| CA2888277C (en) | 2012-10-19 | 2023-09-05 | Txp Pharma Gmbh | Alpha- and gamma-msh analogues |
| WO2014153221A2 (en) | 2013-03-14 | 2014-09-25 | Questcor Pharmaceuticals, Inc. | Acth for treatment of acute respiratory distress syndrome |
| EP2970388B1 (en) | 2013-03-15 | 2018-07-25 | Rhythm Pharmaceuticals, Inc. | Peptide compositions |
| JP6538025B2 (ja) * | 2013-03-15 | 2019-07-03 | リズム・ファーマシューティカルズ・インコーポレイテッド | 医薬組成物 |
| DK3134105T3 (da) | 2014-04-22 | 2021-02-22 | Txp Pharma Gmbh | Peptidanaloger med én eller flere forgrenede aminosyreprober |
| SG10202101510XA (en) * | 2015-09-30 | 2021-03-30 | Rhythm Pharmaceuticals Inc | Method of treating melanocortin-4 receptor pathway-associated disorders |
| WO2017066754A1 (en) * | 2015-10-15 | 2017-04-20 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Compositions and methods for the treatment of depression and anxiety |
| US11542302B2 (en) | 2015-10-15 | 2023-01-03 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Modulators of melanocortin receptors for the treatment of depression and anxiety |
| US20190255142A1 (en) * | 2016-10-17 | 2019-08-22 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Novel modulators of melanocortin receptors for the treatment of depression and anxiety |
| US20200223889A1 (en) * | 2017-03-15 | 2020-07-16 | Novo Nordisk A/S | Bicyclic Compounds Capable of Binding to Melanocortin 4 Receptor |
| EP3773897A1 (en) | 2018-04-06 | 2021-02-17 | Rhythm Pharmaceuticals, Inc. | Compositions for treating kidney disease |
| US20210221867A1 (en) * | 2018-05-15 | 2021-07-22 | Novo Nordisk A/S | Compounds Capable of Binding to Melanocortin 4 Receptor |
| US11992537B2 (en) * | 2018-05-23 | 2024-05-28 | Provincial Health Services Authority | Radiolabeled melanocortin 1 receptor-specific alpha-melanocyte-stimulating hormone analogues for imaging or therapy |
| US11396535B2 (en) | 2019-03-01 | 2022-07-26 | Provincial Health Services Authority | Cyclic peptide analogs of melanocortin and amanitin and methods of making such |
| KR20230095956A (ko) * | 2020-09-24 | 2023-06-29 | 리듬 파마슈티컬즈, 인코포레이티드 | 멜라노코르틴-4 수용체 경로 관련 장애를 치료하는 방법 |
| KR20240035939A (ko) * | 2021-03-24 | 2024-03-19 | 글로 파마, 인크. | 피부 색소침착을 감소시키기 위한 펩타이드 및 방법 |
| JP2024522348A (ja) * | 2021-05-27 | 2024-06-18 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | Ｍｃ３ｒアゴニストペプチド |
| WO2024083843A1 (en) | 2022-10-18 | 2024-04-25 | Confo Therapeutics N.V. | Amino acid sequences directed against the melanocortin 4 receptor and polypeptides comprising the same for the treatment of mc4r-related diseases and disorders |
| WO2025123059A1 (en) * | 2023-12-07 | 2025-06-12 | Endevica Bio, Inc. | Non-naturally occurring melanocortin analogs and uses thereof for treating substance use disorders |
| CN120699097A (zh) * | 2024-09-03 | 2025-09-26 | 万邦德制药集团有限公司 | 一种二硫环肽化合物及其制备方法和应用 |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US613874A (en) | 1898-11-08 | George e | ||
| US1613874A (en) | 1922-03-29 | 1927-01-11 | Miner Inc W H | Friction draft gear |
| US5652214A (en) | 1989-06-05 | 1997-07-29 | Cephalon, Inc. | Treating disorders by application of insulin-like growth factors and analogs |
| US5672659A (en) | 1993-01-06 | 1997-09-30 | Kinerton Limited | Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides |
| US5595760A (en) | 1994-09-02 | 1997-01-21 | Delab | Sustained release of peptides from pharmaceutical compositions |
| US5665702A (en) | 1995-06-06 | 1997-09-09 | Biomeasure Incorporated | Ionic molecular conjugates of N-acylated derivatives of poly(2-amino-2-deoxy-D-glucose) and polypeptides |
| US5916883A (en) | 1996-11-01 | 1999-06-29 | Poly-Med, Inc. | Acylated cyclodextrin derivatives |
| SE9700620D0 (sv) | 1997-02-21 | 1997-02-21 | Wapharm Ab | Cykliska peptider med selektivitet för MSH-receptor subtyper |
| US6350430B1 (en) | 1997-10-27 | 2002-02-26 | Lion Bioscience Science Ag | Melanocortin receptor ligands and methods of using same |
| US6127381A (en) * | 1998-04-28 | 2000-10-03 | Basu; Amaresh | Isoquinoline compound melanocortin receptor ligands and methods of using same |
| JP3790102B2 (ja) * | 1998-07-27 | 2006-06-28 | アイオワ ステイト ユニバーシティ リサーチ ファウンデーション，インコーポレイティド | メラノコルチン−４レセプター遺伝子、並びに動物における脂質含量、体重増加及び／又は食物消費量のマーカーとしての使用 |
| EP1119252A4 (en) | 1998-08-21 | 2004-03-03 | Childrens Medical Center | USE OF MELANIN FOR INHIBITING ANGIOGENESIS AND MACULAR DEGENERATION |
| US6716810B1 (en) | 1998-12-09 | 2004-04-06 | Eleanor Roosevelt Institute | Composition and method for regulation of body weight and associated conditions |
| US6603058B1 (en) | 1998-12-09 | 2003-08-05 | Oklahoma Medical Research Foundation | Non-human animal model for obesity and uses thereof |
| ATE393783T1 (de) | 1999-03-29 | 2008-05-15 | Procter & Gamble | Melanocortinrezeptor-liganden |
| US6579968B1 (en) * | 1999-06-29 | 2003-06-17 | Palatin Technologies, Inc. | Compositions and methods for treatment of sexual dysfunction |
| US7176279B2 (en) | 2000-06-28 | 2007-02-13 | Palatin Technologies, Inc. | Cyclic peptide compositions and methods for treatment of sexual dysfunction |
| ATE409410T1 (de) | 1999-11-12 | 2008-10-15 | Merck & Co Inc | Zellen mit defizientem melanocortin-3-rezeptor, transgene mäuse und verfahren zur auswahl von substanzen, die das körpergewicht regulieren können |
| US6600015B2 (en) | 2000-04-04 | 2003-07-29 | Hoffmann-La Roche Inc. | Selective linear peptides with melanocortin-4 receptor (MC4-R) agonist activity |
| KR20030017571A (ko) * | 2000-06-28 | 2003-03-03 | 화이자 프로덕츠 인크. | 멜라노코르틴 수용체 리간드 |
| US6720324B2 (en) | 2000-07-05 | 2004-04-13 | Synaptic Pharmaceutical Corporation | Selective melanin concentrating hormone-1 (MCH1) receptor antagonists and uses thereof |
| WO2002023184A1 (en) | 2000-09-13 | 2002-03-21 | Eleanor Roosevelt Institute | Method for treatment of insulin resistance in obesity and diabetes |
| US20030113263A1 (en) | 2001-02-13 | 2003-06-19 | Oregon Health And Sciences University, A Non-Profit Organization | Methods and reagents for using mammalian melanocortin receptor antagonists to treat cachexia |
| JP2004532838A (ja) | 2001-03-02 | 2004-10-28 | ブリストル−マイヤーズ スクイブ カンパニー | メラノコルチン受容体のモデュレーターとして有用な化合物及びそれを含む製薬組成物 |
| US6770645B2 (en) * | 2001-03-16 | 2004-08-03 | Pfizer Inc. | Pharmaceutically active compounds |
| AU2002322466B2 (en) * | 2001-07-11 | 2007-08-30 | Palatin Technologies, Inc. | Linear and cyclic melanocortin receptor-specific peptides |
| US7034004B2 (en) | 2002-05-07 | 2006-04-25 | University Of Florida | Peptides and methods for the control of obesity |
| US20040128136A1 (en) * | 2002-09-20 | 2004-07-01 | Irani Pourang Polad | Internet voice browser |
| WO2005000338A1 (en) * | 2003-06-19 | 2005-01-06 | Eli Lilly And Company | Uses of melanocortin-3 receptor (mc3r) agonist peptides |
| EP1644023A2 (en) * | 2003-06-19 | 2006-04-12 | Eli Lilly And Company | Melanocortin recptor 4(mc4) agonists and their uses |
| US7084111B2 (en) | 2003-06-23 | 2006-08-01 | University Of Florida Research Foundation, Inc. | Melanocortin receptor templates, peptides, and use thereof |
| JP4754487B2 (ja) * | 2003-08-20 | 2011-08-24 | エミスフィアー テクノロジーズ インコーポレイテッド | グルカゴン様ペプチド（ｇｌｐ）−１化合物またはメラノコルチン４受容体（ｍｃ４）アゴニストペプチドの経口デリバリーのための化合物、方法および製剤 |
| CA2532026C (en) * | 2003-08-20 | 2012-04-17 | Eli Lilly And Company | Compounds, methods and formulations for the oral delivery of a glucagon like peptide (glp)-1 compound or an melanocortin 4 receptor (mc4) agonist peptide |
| US20050192286A1 (en) * | 2003-10-22 | 2005-09-01 | Neurocrine Biosciences, Inc. | Ligands of melanocortin receptors and compositions and methods related thereto |
| DE10355559A1 (de) | 2003-11-21 | 2005-06-23 | Orthogen Ag | Transskin |
| WO2005060985A1 (en) | 2003-12-10 | 2005-07-07 | Merck & Co., Inc. | Inhibition of voluntary ethanol consumption with selective melanocortin 4-receptor agonists |
| JP2007530674A (ja) | 2004-03-29 | 2007-11-01 | イーライ リリー アンド カンパニー | 連続注入によって投与されるメラノコルチン−４受容体（ｍｃ４ｒ）アゴニストペプチドの使用 |
| JP5449673B2 (ja) | 2004-10-08 | 2014-03-19 | クリヌベール、ファーマスーティカルズ、リミテッド | 対象者におけるメラニン形成を誘導するための組成物および方法 |
| WO2006073772A1 (en) | 2005-01-05 | 2006-07-13 | Eli Lilly And Company | Polyethylene glycol linked mc4r or mc3r agonist peptides |
| WO2006073771A2 (en) | 2005-01-05 | 2006-07-13 | Eli Lilly And Company | Polyethylene glycol linked mc4r or mc3r agonist peptides |
| RU2439079C2 (ru) * | 2005-07-08 | 2012-01-10 | Сосьете Де Консей Де Решерш Э Д'Аппликасьон Сьентифик С.А.С. | Лиганды рецепторов меланокортинов |
| US8466104B2 (en) | 2005-08-26 | 2013-06-18 | Abbvie Inc. | Therapeutically active alpha MSH analogues |
-
2006
- 2006-07-10 RU RU2009131092/04A patent/RU2439079C2/ru active
- 2006-07-10 CN CN2006800324235A patent/CN101257916B/zh active Active
- 2006-07-10 PL PL10170694T patent/PL2236151T3/pl unknown
- 2006-07-10 HU HUE12188784A patent/HUE037147T2/hu unknown
- 2006-07-10 SI SI200632406T patent/SI3354273T1/sl unknown
- 2006-07-10 ES ES10170694T patent/ES2386862T3/es active Active
- 2006-07-10 EP EP17202836.7A patent/EP3354273B1/en active Active
- 2006-07-10 ES ES10182566.9T patent/ES2604328T3/es active Active
- 2006-07-10 PT PT121887848T patent/PT2548568T/pt unknown
- 2006-07-10 PL PL10182566T patent/PL2286825T3/pl unknown
- 2006-07-10 EP EP21163411.8A patent/EP3925614A3/en active Pending
- 2006-07-10 EP EP10182566.9A patent/EP2286825B1/en active Active
- 2006-07-10 RU RU2008104803/04A patent/RU2380372C2/ru active
- 2006-07-10 EP EP10170694A patent/EP2236151B1/en active Active
- 2006-07-10 CA CA2793119A patent/CA2793119C/en active Active
- 2006-07-10 HU HUE17202836A patent/HUE055154T2/hu unknown
- 2006-07-10 PL PL12188784T patent/PL2548568T3/pl unknown
- 2006-07-10 KR KR1020097022845A patent/KR101232201B1/ko active Active
- 2006-07-10 DK DK17202836.7T patent/DK3354273T3/da active
- 2006-07-10 EP EP06786665A patent/EP1915167A4/en not_active Withdrawn
- 2006-07-10 WO PCT/US2006/026586 patent/WO2007008704A2/en not_active Ceased
- 2006-07-10 PT PT101825669T patent/PT2286825T/pt unknown
- 2006-07-10 CA CA3228910A patent/CA3228910A1/en active Pending
- 2006-07-10 CN CN202411273113.9A patent/CN119119190A/zh active Pending
- 2006-07-10 DK DK10182566.9T patent/DK2286825T3/en active
- 2006-07-10 CA CA2614615A patent/CA2614615C/en active Active
- 2006-07-10 NZ NZ565217A patent/NZ565217A/en unknown
- 2006-07-10 ES ES12188784.8T patent/ES2663916T3/es active Active
- 2006-07-10 ES ES17202836T patent/ES2877349T3/es active Active
- 2006-07-10 SG SG201004921-1A patent/SG163585A1/en unknown
- 2006-07-10 US US11/988,533 patent/US8039435B2/en active Active
- 2006-07-10 PT PT10170694T patent/PT2236151E/pt unknown
- 2006-07-10 HU HUE10182566A patent/HUE031731T2/en unknown
- 2006-07-10 AU AU2006269261A patent/AU2006269261B2/en active Active
- 2006-07-10 CN CN200910174061A patent/CN101676298A/zh active Pending
- 2006-07-10 DK DK10170694.3T patent/DK2236151T3/da active
- 2006-07-10 PT PT172028367T patent/PT3354273T/pt unknown
- 2006-07-10 NZ NZ580806A patent/NZ580806A/en not_active Application Discontinuation
- 2006-07-10 JP JP2008520417A patent/JP4734411B2/ja active Active
- 2006-07-10 CN CN201610168908.2A patent/CN105837661B/zh active Active
- 2006-07-10 EP EP12188784.8A patent/EP2548568B1/en active Active
- 2006-07-10 PL PL17202836T patent/PL3354273T3/pl unknown
- 2006-07-10 CA CA3044795A patent/CA3044795A1/en not_active Abandoned
- 2006-07-10 CN CN201310495024.4A patent/CN103755786B/zh active Active
- 2006-07-10 DK DK12188784.8T patent/DK2548568T3/en active
- 2006-07-10 KR KR1020087002955A patent/KR100997177B1/ko active Active
-
2008
- 2008-01-02 IL IL188545A patent/IL188545A/en active IP Right Grant
-
2009
- 2009-10-25 IL IL201732A patent/IL201732A/en active IP Right Grant
- 2009-10-28 AU AU2009230799A patent/AU2009230799B2/en active Active
- 2009-11-19 JP JP2009263603A patent/JP5889513B2/ja active Active
-
2011
- 2011-03-29 US US13/074,565 patent/US9458195B2/en active Active
-
2013
- 2013-08-08 JP JP2013165312A patent/JP2013253090A/ja active Pending
-
2015
- 2015-07-14 JP JP2015140154A patent/JP5965520B2/ja active Active
-
2016
- 2016-06-22 IL IL246392A patent/IL246392A/en active IP Right Grant
- 2016-09-07 US US15/257,970 patent/US20160368962A1/en not_active Abandoned
-
2017
- 2017-05-05 US US15/587,426 patent/US9850280B2/en active Active
- 2017-12-04 US US15/830,038 patent/US20180105557A1/en not_active Abandoned
-
2018
- 2018-07-09 US US16/029,837 patent/US20180305406A1/en not_active Abandoned
-
2019
- 2019-12-04 US US16/702,661 patent/US20200095281A1/en not_active Abandoned
-
2021
- 2021-12-06 NL NL301150C patent/NL301150I2/nl unknown
- 2021-12-07 BE BE2021C557C patent/BE2021C557I2/nl unknown
- 2021-12-14 FR FR21C1060C patent/FR21C1060I2/fr active Active
- 2021-12-15 HU HUS2100054C patent/HUS2100054I1/hu unknown
-
2022
- 2022-01-10 US US17/572,115 patent/US20220127305A1/en not_active Abandoned